Neuberger Berman Group
SRPT icon

Neuberger Berman Group’s Sarepta Therapeutics SRPT Stock Holding History

Neuberger Berman Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,232
Closed -$266K – 2407
2026
Q1 		$266K Buy
12,232
+1,853
+18% +$35.9K ﹤0.01% 1888
2025
Q4 		$223K Buy
+10,379
New +$219K ﹤0.01% 1920
2025
Q2 		– Sell
-5,530
Closed -$353K – 2116
2025
Q1 		$353K Buy
5,530
+1,211
+28% +$127K ﹤0.01% 1648
2024
Q4 		$525K Sell
4,319
-116,387
-96% -$14.3M ﹤0.01% 1513
2024
Q3 		$15.1M Buy
120,706
+32,255
+36% +$4.46M 0.01% 717
2024
Q2 		$14M Buy
88,451
+2,790
+3% +$358K 0.01% 717
2024
Q1 		$11.1M Sell
85,661
-54,621
-39% -$6.69M 0.01% 765
2023
Q4 		$13.5M Buy
140,282
+69,061
+97% +$6.62M 0.01% 839
2023
Q3 		$8.63M Sell
71,221
-28
-0% -$3.17K 0.01% 767
2023
Q2 		$8.16M Buy
71,249
+22
+0% +$2.84K 0.01% 782
2023
Q1 		$9.82M Buy
71,227
+66,988
+1,580% +$8.69M 0.01% 751
2022
Q4 		$549K Sell
4,239
-11
-0.3% -$1.27K ﹤0.01% 1421
2022
Q3 		$470K Buy
4,250
+105
+3% +$10.6K ﹤0.01% 1493
2022
Q2 		$311K Buy
4,145
+1,305
+46% +$96K ﹤0.01% 1632
2022
Q1 		$222K Buy
+2,840
New +$217K ﹤0.01% 1778
2021
Q1 		– Sell
-37,779
Closed -$6.42M – 1817
2020
Q4 		$6.42M Buy
+37,779
New +$5.6M 0.01% 859
2019
Q3 		– Sell
-61,500
Closed -$9.35M – 1594
2019
Q2 		$9.35M Buy
61,500
+1,500
+3% +$182K 0.01% 769
2019
Q1 		$7.15M Sell
60,000
-2,053
-3% -$264K 0.01% 792
2018
Q4 		$6.77M Sell
62,053
-69,500
-53% -$8.69M 0.01% 791
2018
Q3 		$21.2M Sell
131,553
-667
-0.5% -$91.2K 0.02% 630
2018
Q2 		$17.5M Buy
132,220
+107,042
+425% +$10.1M 0.02% 667
2018
Q1 		$1.86M Buy
25,178
+7,403
+42% +$494K ﹤0.01% 1038
2017
Q4 		$989K Sell
17,775
-7,225
-29% -$383K ﹤0.01% 1212
2017
Q3 		$1.13M Buy
+25,000
New +$999K ﹤0.01% 1127

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Neuberger Berman Group's SRPT Position: Q2 2026 in Review

Neuberger Berman Group sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 12,232 shares — an estimated $266K sold.

Neuberger Berman Group first reported a position in SRPT in Q3 2017 and held it in 24 quarters. The position peaked at $21.2M in Q3 2018. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Neuberger Berman Group reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Neuberger Berman Group sold 12,232 Sarepta Therapeutics shares in Q2 2026, an estimated $266K.
  • Neuberger Berman Group first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 24 quarters.
  • Neuberger Berman Group's Sarepta Therapeutics position peaked at $21.2M in Q3 2018.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.